Novasep invests EUR three million to boost its HPAPI manufacturing capabilities

23-Jul-2012 - France

Novasep announces a EUR three million investment to expand its Highly Potent API (HPAPI) manufacturing capabilities at its facility in Le Mans, France. The expansion has been designed to allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies.

Demand in the pharmaceutical industry has sharply increased for the manufacture of targeted and potent drugs that improve efficacy and reduce side effects, such as antibody-drug conjugates (ADCs). The new Novasep Le Mans facility adds to Novasep’s comprehensive global strategy for total synthesis of ADCs, including toxin and monoclonal antibodies (mAb) production, mAb-toxin coupling, downstream processing and formulation.

In the new facility, Novasep will be able to perform cryogenic chemistry at minus 60 degrees C in hastelloy reactors, large-scale HPLC chromatography and drying in confined areas to manufacture ADC toxins at commercial scale. The plant expansion is expected to be fully operational by the beginning of 2013. In its expanded cGMP facility, Novasep will be able to perform the synthesis, purification and isolation of extremely potent compounds with an OEL (occupational exposure limit) lower than 30 ng/m3 at multi-kg scale per batch.

Other news from the department manufacturing

More news from our other portals

So close that even
molecules turn red...